{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:02:32Z","timestamp":1790384552863,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472171"],"award-info":[{"award-number":["81472171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672299"],"award-info":[{"award-number":["81672299"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"State Scholarship Fund of China","award":["201308330145"],"award-info":[{"award-number":["201308330145"]}]},{"name":"Project of Health and Family Planning Commission of Zhejiang Province, China","award":["2017KY058"],"award-info":[{"award-number":["2017KY058"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-017-3720-8","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T05:30:11Z","timestamp":1514957411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment"],"prefix":"10.1186","volume":"18","author":[{"given":"Jianya","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"issue":"1","key":"3720_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A, et al. Cancer statistics. CA Cancer J Clin. 2012;62(1):10\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"3720_CR2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.6004\/jnccn.2010.0056","volume":"8","author":"DS Ettinger","year":"2010","unstructured":"Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, et al. Non-small cell lung cancer. J Natl Compr Cancer Netw. 2010;8(7):740\u2013801.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"8","key":"3720_CR3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","volume":"115","author":"DW Wong","year":"2009","unstructured":"Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723\u201333.","journal-title":"Cancer"},{"issue":"1","key":"3720_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JTO.0b013e31815e8b60","volume":"3","author":"K Inamura","year":"2008","unstructured":"Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1):13\u20137. \nhttps:\/\/doi.org\/10.1097\/JTO.0b013e31815e8b60\n\n.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3720_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1245\/s10434-009-0808-7","volume":"17","author":"T Takahashi","year":"2010","unstructured":"Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, Okubo K, Manabe T, Date H. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17(3):889\u201397. \nhttps:\/\/doi.org\/10.1245\/s10434-009-0808-7\n\n.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"3720_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.lungcan.2012.03.013","volume":"77","author":"T Fukui","year":"2012","unstructured":"Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, Matsuo K, Mitsudomi T. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer. 2012;77(2):319\u201325. \nhttps:\/\/doi.org\/10.1016\/j.lungcan.2012.03.013\n\n. Epub 2012 Apr 6","journal-title":"Lung Cancer"},{"issue":"4","key":"3720_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1097\/JTO.0b013e31820cf053","volume":"6","author":"DR Camidge","year":"2011","unstructured":"Camidge DR, Kono SA, Lu X, Okuyama S, Bar\u00f3n AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W, Doebele RC. Anaplastic lymphoma kinase gene arrangement in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011;6(4):774\u201380. \nhttps:\/\/doi.org\/10.1097\/JTO.0b013e31820cf053\n\n.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"3720_CR8","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1097\/JTO.0b013e3182208fc2","volume":"6","author":"JO Lee","year":"2011","unstructured":"Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YW, Heo DS, Bang YJ. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol. 2011;6(9):1474\u201380. \nhttps:\/\/doi.org\/10.1097\/JTO.0b013e3182208fc2\n\n.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"3720_CR9","first-page":"1477","volume":"11","author":"SJ Rodig","year":"2010","unstructured":"Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 2010;11(12):1477\u201390.","journal-title":"Curr Opin Investig Drugs"},{"issue":"18","key":"3720_CR10","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui JJ, Tran-Dub\u00e9 M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, McTigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of Mesenchymal-epithelial transition factor (c-MET) Kinase and Anaplastic lymphoma Kinase (ALK). J Med Chem. 2011;54(18):6342\u201363.","journal-title":"J Med Chem"},{"issue":"18","key":"3720_CR11","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, J\u00e4nne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693\u2013703. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1006448\n\n.","journal-title":"N Engl J Med"},{"issue":"10","key":"3720_CR12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","volume":"13","author":"DR Camidge","year":"2012","unstructured":"Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, J\u00e4nne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011\u20139.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3720_CR13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","volume":"12","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004\u201312.","journal-title":"Lancet Oncol"},{"issue":"25","key":"3720_CR14","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, J\u00e4nne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med"},{"issue":"2","key":"3720_CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/2278-330X.110506","volume":"2","author":"A Sahu","year":"2013","unstructured":"Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: a comprehensive review. South Asian J Cancer. 2013;2(2):91\u20137.","journal-title":"South Asian J Cancer"},{"key":"3720_CR16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1186\/1471-2407-14-683","volume":"14","author":"H Qian","year":"2014","unstructured":"Qian H, Gao F, Wang H, Ma F. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta analysis of clinical trials. BMC Cancer. 2014;14:683.","journal-title":"BMC Cancer"},{"issue":"5","key":"3720_CR17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00330-014-3516-z","volume":"25","author":"JY Zhou","year":"2015","unstructured":"Zhou JY, Zheng J, Yu ZF, Xiao WB, Zhao J, Sun K, Wang B, Chen X, Jiang LN, Ding W, Zhou JY. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol. 2015;25(5):1257\u201366.","journal-title":"Eur Radiol"},{"issue":"23","key":"3720_CR18","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377.","journal-title":"N Engl J Med"},{"key":"3720_CR19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2016.04.006","volume":"97","author":"T Yoshida","year":"2016","unstructured":"Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T, Yatabe Y. Clinical impact of crizotinib on central nervous system progression inALK-positive non-small lung cancer. Lung Cancer. 2016;97:43\u20137.","journal-title":"Lung Cancer"},{"issue":"5","key":"3720_CR20","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/JTO.0000000000000468","volume":"10","author":"G Metro","year":"2015","unstructured":"Metro G, Lunardi G, Floridi P, Pascali JP, Marcomigni L, Chiari R, Ludovini V, Crin\u00f2 L, Gori S. CSF concentration of Crizotinib in two ALK-positive non-small-cell lung cancer patients with CNSMetastases deriving clinical benefit from treatment. J Thorac Oncol. 2015;10(5):e26\u20137.","journal-title":"J Thorac Oncol"},{"issue":"15","key":"3720_CR21","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","volume":"29","author":"DB Costa","year":"2011","unstructured":"Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, Wilner KD. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443\u20135.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3720-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T05:30:21Z","timestamp":1514957421000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3720-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3720-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]},"article-number":"10"}}